Polomar Health Services (PMHS) Non-Current Debt (2025 - 2026)
Polomar Health Services (PMHS) posted Non-Current Debt of $166368.0 for Q1 2026, up 166.03% on a QoQ basis from $62538.0 in Q4 2025.
Powered by 
Analysis
Polomar Health Services (PMHS) Non-Current Debt (2025 - 2026) Analysis & Trends
Polomar Health Services has reported Non-Current Debt for 2 years, with the latest figure at $166368.0 in Q1 2026.
- On a quarterly basis, Non-Current Debt changed N/A year-over-year to $166368.0 in Q1 2026; TTM through Mar 2026 was $166368.0, a N/A change from a year earlier, with the FY2025 full-year figure at $62538.0, changed N/A from the prior year.
- Non-Current Debt was $166368.0 for Q1 2026 at Polomar Health Services, up from $62538.0 in the prior quarter.
- The five-year high for Non-Current Debt was $808875.0 in Q2 2025, with the low at $62538.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 12.09 Bn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 11.61 Bn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 150.67 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 2.57 Bn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 20.74 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 1.26 Bn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 280.16 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 609.56 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | - |
| 10 | Polomar Health Services | 5.66 Mn | 5.48 Mn | 935,916.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 166,368.00 |
| Dec 31, 2025 | 62,538.00 |
| Jun 30, 2025 | 808,875.00 |